Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Molecular signature of Epstein-Barr virus infection in MS brain lesions.

Moreno MA, Or-Geva N, Aftab BT, Khanna R, Croze E, Steinman L, Han MH.

Neurol Neuroimmunol Neuroinflamm. 2018 Jun 7;5(4):e466. doi: 10.1212/NXI.0000000000000466. eCollection 2018 Jul.

2.

Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide.

Aversa F, Bachar-Lustig E, Or-Geva N, Prezioso L, Bonomini S, Manfra I, Monti A, Schifano C, Zlotnikov-Klionsky Y, Martelli MF, Sammarelli G, Sassi M, Soli M, Giuliodori S, Benecchi M, Giuliani N, Lohr F, Pratissoli S, Reisner Y.

Blood Adv. 2017 Oct 30;1(24):2166-2175. doi: 10.1182/bloodadvances.2017009423. eCollection 2017 Nov 14.

3.

Towards 'off-the-shelf' genetically modified T cells: prolonging functional engraftment in mice by CD8 veto T cells.

Or-Geva N, Gidron-Budovsky R, Radomir L, Edelstein Y, Singh AK, Sidlik-Muskatel R, Ophir E, Bachar-Lustig E, Reisner Y.

Leukemia. 2018 Apr;32(4):1039-1041. doi: 10.1038/leu.2017.332. Epub 2017 Nov 20. No abstract available.

PMID:
29151584
4.

The evolution of T-cell depletion in haploidentical stem-cell transplantation.

Or-Geva N, Reisner Y.

Br J Haematol. 2016 Mar;172(5):667-84. doi: 10.1111/bjh.13868. Epub 2015 Dec 18. Review.

PMID:
26684279
5.

The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.

Or-Geva N, Reisner Y.

Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S14-20. doi: 10.1038/bmt.2015.89.

PMID:
26039201
6.

Exercising 'veto' power to make haploidentical hematopoietic stem cell transplantation a safe modality for induction of immune tolerance.

Or-Geva N, Reisner Y.

Regen Med. 2015;10(3):239-42. doi: 10.2217/rme.14.94. No abstract available.

PMID:
25933232
7.

Megadose stem cell administration as a route to mixed chimerism.

Or-Geva N, Reisner Y.

Curr Opin Organ Transplant. 2014 Aug;19(4):334-41. doi: 10.1097/MOT.0000000000000095. Review.

PMID:
24905022
8.

A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells.

Lask A, Ophir E, Or-Geva N, Cohen-Fredarow A, Afik R, Eidelstein Y, Reich-Zeliger S, Nathansohn B, Edinger M, Negrin RS, Hagin D, Reisner Y.

Blood. 2013 Apr 11;121(15):3033-40. doi: 10.1182/blood-2012-06-432443. Epub 2013 Feb 27.

9.

Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells.

Ophir E, Or-Geva N, Gurevich I, Tal O, Eidelstein Y, Shezen E, Margalit R, Lask A, Shakhar G, Hagin D, Bachar-Lustig E, Reich-Zeliger S, Beilhack A, Negrin R, Reisner Y.

Blood. 2013 Feb 14;121(7):1220-8. doi: 10.1182/blood-2012-07-441493. Epub 2012 Dec 5.

10.

Induction of transplantation tolerance in haploidenical transplantation under reduced intensity conditioning: the role of ex-vivo generated donor CD8+ T cells with central memory phenotype.

Ophir E, Eidelstein Y, Bachar-Lustig E, Hagin D, Or-Geva N, Lask A, Reisner Y.

Best Pract Res Clin Haematol. 2011 Sep;24(3):393-401. doi: 10.1016/j.beha.2011.05.007. Epub 2011 Jul 13. Review.

PMID:
21925092

Supplemental Content

Loading ...
Support Center